Arcturus Therapeutics (ARCT) Stock Statistics & Valuation Metrics

Arcturus Therapeutics has a market cap or net worth of $199.81M. The enterprise value is -$1.54M.

Arcturus Therapeutics has 28,423,069 shares outstanding. The number of shares has decreased by -2.65% in one year.

Arcturus Therapeutics’s return on equity (ROE) is -0.31 and return on invested capital (ROIC) is -31.36%.

The current PE Ratio of Arcturus Therapeutics is ―. Arcturus Therapeutics’s PEG ratio is 0.13.

In the last 12 months, Arcturus Therapeutics had revenue of 67.22M and earned -65.78M in profits. Earnings per share was -2.40.

In the last 12 months, operating cash flow was -58.57M and capital expenditures -318.66K, giving a free cash flow of -58.89M billion.

Arcturus Therapeutics pays an annual dividend of $0.06, resulting in a dividend yield of ―

Arcturus Therapeutics upcoming earnings date is Aug 10, 2026, After Close (Confirmed).

Arcturus Therapeutics as a current ratio of 6.64, with Debt / Equity ratio of 10.28%

In the past 12 months, Arcturus Therapeutics has paid 0.00 in taxes.

Arcturus Therapeutics EV to EBITDA ratio is 0.53, with an EV/FCF ratio of 0.51.

Arcturus Therapeutics has $211.38M in cash and marketable securities with $19.68M in debt, giving a net cash position of $191.69M billion.

Gross margin is 91.18%, with operating margin of -111.51%, and net profit margin of -97.86%.

The average price target for Arcturus Therapeutics is $18.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy